September 16, 2019
A few important new resources are up on AVAC.org
. Read on for highlights and links.
Don’t miss AVAC’s Take on Updated WHO Guidance on Hormonal Contraception and HIV Risk
. You’ll learn “business as usual” is a grave concern in light of the World Health Organization’s (WHO) updated guidance
on “Hormonal Contraceptive Eligibility for Women at High Risk of HIV”. The changed status of the hormonal contraceptive DMPA stems from a review that was prompted by the results of the ECHO Trial.
F/TAF and Women
In our blog, “A New Oral PrEP Strategy Is On the Horizon, But Who’s Going to Get It?
” you’ll get the details on a potential new oral PrEP strategy using F/TAF, which inched a step closer to availability—though not necessarily for all people who need it. The blog provides information on what happened at an Antimicrobial Drugs Advisory Committee meeting on F/TAF for PrEP, convened by the US Food and Drug Administration—and what needs to happen next.
PrEP and the Challenge of Continuation
Watch the webinar, Identifying PrEP Continuation Challenges and Approaches to Support Success,
to hear implementers from Kenya (Jhpiego
) and Zimbabwe (PZAT)
share PrEP continuation challenges, successes, and approaches. And learn more about findings from a recent think tank our Prevention Market Manager project
co-convened with a number of partners on defining impact and success in the context of PrEP, and key considerations for measuring and monitoring continued and effective use.
Fellows in 2020
Apply to become an AVAC fellow, or send this application
to someone who you know belongs in AVAC’s 2020 class of Advocacy Fellows. AVAC’s Advocacy Fellows Program
has been supporting and expanding the capacity of advocates and organizations to accelerate, shape and monitor biomedical HIV prevention research and implementation since 2009. Our Fellows have gone on to become leaders in the HIV movement in their communities, countries and globally. Don’t miss your chance to join the next class—deadline is September 20th!